Table 1.
Characteristics of patients followed in September 2003 in the EuroSIDA study
| SE (n = 1888) | WC (n = 1911) | NE (n = 1974) | EC (n = 890) | EE (n = 441) | p-value | |
|---|---|---|---|---|---|---|
| Age, yrs; median (IQR) | 41 (37–47) | 43 (39–51) | 44 (39–52) | 36 (31–44) | 30 (24–39) | <0.001 |
| Female, % | 28 | 23 | 18 | 30 | 31 | <0.001 |
| IDU, % | 29 | 14 | 11 | 30 | 51 | <0.001 |
| AIDS diagnosis, n(%) | 509 (27) | 588 (31) | 684 (35) | 214 (24) | 117 (26.5) | <0.001 |
| HCV, % | 30 | 17.5 | 13 | 34 | 33 | <0.001 |
| CD4 count cells/mm3; median (IQR) | 459 (291–679) | 429 (281–601) | 449 (300–620) | 484 (297–659) | 337 (185–593) | <0.001 |
| Nadir CD4 count cells/mm3; median (IQR) | 150 (57–263) | 131 (49–229) | 113 (42–200) | 144 (65–270) | 270 (131–476) | <0.001 |
| Time from HIV diagnosis, mths; median (IQR) | 122 (78–164) | 134 (96–177) | 136 (96–186) | 75 (39–119) | 32 (18–53) | <0.001 |
| On HAART, % | 77 | 80 | 84 | 78 | 30 | <0.001 |
SE: Spain, Portugal, Italy, Greece, Serbia and Montenegro, Israel, Argentina; WC: France, Belgium, south Germany, Luxembourg, Switzerland, Austria; NE: United Kingdom, Ireland, Netherlands, north Germany, Denmark, Sweden, Norway; EC: Poland, Czech Republic, Slovakia, Hungary, Romania; EE: Estonia, Latvia, Lithuania, Belarus, Ukraine, Russia